Director Robert J. Gould sells 15,000 Fulcrum (FULC) shares under 10b5-1 plan

Rhea-AI Filing Summary

Fulcrum Therapeutics director Robert J. Gould reported an automatic stock sale under a pre-set trading plan. On 02/02/2026, he sold 15,000 shares of Fulcrum Therapeutics common stock at a weighted average price of $10.7238 per share, coded as an open market sale.

The transaction was executed pursuant to a Rule 10b5-1 trading plan that he adopted on August 1, 2025, which allows pre-arranged trades. After this sale, Gould beneficially owned 454,864 shares of Fulcrum Therapeutics common stock in direct ownership.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gould Robert J

(Last) (First) (Middle)

C/O FULCRUM THERAPEUTICS, INC.

26 LANDSDOWNE STREET

(Street)

CAMBRIDGE MA 02139

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Fulcrum Therapeutics, Inc. [ FULC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/02/2026		S(1)		15,000	D	$10.7238(2)	454,864	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 1, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.48 to $11.10, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

	/s/ Greg Tourangeau, as attorney-in-fact for Robert J. Gould	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Fulcrum Therapeutics (FULC) report for Robert J. Gould?

Fulcrum Therapeutics director Robert J. Gould reported selling 15,000 shares of common stock. The sale occurred on February 2, 2026, as an open market transaction, and was executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 1, 2025.

At what price did Robert J. Gould sell Fulcrum Therapeutics (FULC) shares?

Robert J. Gould sold his Fulcrum Therapeutics shares at a weighted average price of $10.7238 per share. The filing notes the stock was sold in multiple trades, with individual prices ranging from $10.48 to $11.10, inclusive, during the February 2, 2026 transaction.

How many Fulcrum Therapeutics (FULC) shares does Robert J. Gould own after the reported sale?

After the February 2, 2026 sale, Robert J. Gould beneficially owned 454,864 shares of Fulcrum Therapeutics common stock. The filing shows these shares as directly held, reflecting his remaining ownership position following the 15,000-share disposition reported in the Form 4.

Was the Fulcrum Therapeutics (FULC) insider sale by Robert J. Gould under a Rule 10b5-1 plan?

Yes. The Form 4 states that the sales were effected under a Rule 10b5-1 trading plan adopted by Robert J. Gould on August 1, 2025. Such plans allow insiders to schedule trades in advance, helping separate routine sales from discretionary trading decisions.

What does the weighted average price mean in the Fulcrum Therapeutics (FULC) Form 4 filing?

The weighted average price of $10.7238 reflects multiple individual trades executed between $10.48 and $11.10 per share. The filing notes the reporting person will provide detailed trade breakdowns upon request to Fulcrum Therapeutics, its security holders, or Securities and Exchange Commission staff.

What is Robert J. Gould’s role at Fulcrum Therapeutics (FULC) according to the Form 4?

According to the Form 4, Robert J. Gould is a director of Fulcrum Therapeutics. The filing indicates he is not listed as an officer or 10% owner, and the reported February 2, 2026 stock sale relates to his holdings of the company’s common stock.